Revenue +18.7%Revenue accelerated to AED 1,403 million, driven by strong patient footfall and improved yield from high-value services. EBITDA +59.4%EBITDA increased to AED 306 million, supported by top-line growth and continued cost efficiencies.Net Profit+128.9%Net profit reached AED 148 million, reflecting strong margin expansion and gains from asset optimization.
Patients +12.1%Patient footfall increased, fueled by expanding demand across IVF, oncology, and advanced diagnostics.Oncology +36.7%Oncology revenue surged, driven by oncology network expansion and improved surgical conversion rates. Dividend AED 170mThe Group distributed a full-year dividend of AED 170 million for FY2024 — 47% of reported net profit.
Q2’25 Key Highlights
Abu Dhabi, United Arab Emirates, 6 August 2025:Burjeel Holdings PLC (“Burjeel” or “the Group”), a leading super-specialty healthcare services provider in MENA listed on the Abu Dhabi Securities Exchange (SYMBOL: BURJEEL; ISIN: AEE01119B224), today announced its financial results in accordance with International Financial Reporting Standards (IFRS) for the three-month and six-month periods ended 30 June 2025.
A study conducted in a tertiary care center Dubai, UAE in the by Prof Dr. Syed Arshad Husain currently working as the senior Consultant Pulmonologist at Al Zahra Hospital Dubai two years ago with other eminent team of healthcare professionals, including Prof Bassam Mehboob senior Consultant Pulmonologist at Rashid Hospital (DHA) Dubai.
Prof. Dr. Syed Arshad Husain, Consultant Pulmonologist ,Al Zahra Hospital Dubai
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment
Data underscores the value of early intervention and supports a limited duration dosing approach with sustained long-term benefits
INDIANAPOLIS, August 04, 2025: Eli Lilly and Company (NYSE: LLY) announcedresults from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showingthat participants treated with Kisunla (donanemab-azbt)demonstrated slowing of decline, a benefitthat continued to grow over threeyears compared to an untreated external cohort from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
Advanced minimally invasive procedure restores normal blood flow in rare case of Superior Vena Cava Syndrome(SVCS), ending a four-year health struggle for the young Dubai resident.
The majority of SVCS cases around 60–70% are associated with cancers such as lung cancer or lymphoma, while 30–40% result from long-term use of medical devices like central venous catheters or pacemakers, which can damage vessel walls and lead to narrowing.12
A smaller percentage, around 3–5% are linked to genetic clotting disorders. In very rare cases, the condition has no identifiable underlying cause, as seen in Muhammad Bilal’s case.
Muhammad Bilal with Dr. Roshan Rodney S, Specialist Vascular and Endovascular Surgeon at Aster Hospital Mankhool
Swift diagnosis and emergency surgery prevent fatal complications for Indian expatriate
Untreated infections—whether in the ear, sinuses, or teeth—can quietly spread to the brain and become life-threatening.
4 August2025; Ras Al Khaimah, UAE –In a race against time, doctors at RAK Hospital saved the life of a 32-year-old Indian expatriate laborer after discovering a rare, fast-growing brain infection called a brain abscess — a painful, pus-filled swelling in the brain caused by infection that can rapidly worsen if untreated. The patient, who had been suffering from severe headaches, neck pain, and fever for a week, underwent emergency brain surgery that prevented potentially fatal complications.
UAE News 24/7 